Physician profile
Scott B Kleber
NPI 1730131194
$6,778.95
in general payments reported to CMS, 2019-2025
57 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $406 · 2021: $451 · 2022: $949 · 2023: $1,036 · 2024: $1,473 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $604.09 | 2019-2025 | Evenity, Otezla, Enbrel |
| Abbott Laboratories | $463.00 | 2021-2025 | Freestyle Libre 3 |
| Ucb, INC. | $450.17 | 2023-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Sanofi-Aventis U.S. LLC | $429.11 | 2019-2025 | |
| Lilly USA, LLC | $414.80 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $410.74 | 2019-2025 | Korlym |
| Mannkind Corporation | $393.60 | 2019-2025 | Afrezza |
| Abbvie INC. | $308.48 | 2019-2024 | |
| Novo Nordisk INC | $257.71 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $254.27 | 2021-2025 | Gvoke Hypopen |
| Pfizer INC. | $228.80 | 2019-2025 | |
| Inspire Medical Systems, INC. | $177.19 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $169.89 | 2019-2024 | Austedo Xr, Austedo |
| Ascendis Pharma Endocrinology INC | $166.08 | 2024-2025 | Yorvipath |
| Amarin Pharma, INC. | $132.65 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kleber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.